)
Viking Therapeutics (VKTX) investor relations material
Viking Therapeutics Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.VK2735 maintenance results
At Week 21, weekly VK2735 produced 16.3%–18.7% weight loss across dose groups; the 17.5 mg cohort lost 17.8% (n=118), with no plateau observed.
After switching from weekly dosing, participants maintained up to 96.7% of Week 21 weight loss with every-other-week dosing and up to 90.2% with monthly dosing through Week 33; placebo participants regained ~40% of initial weight loss by Week 12.
Continued 17.5 mg weekly dosing produced 21.7% weight loss from baseline at Week 33, with no plateau observed.
Maintenance-phase GI adverse-event rates were similar to placebo, with low GI event rates after titration; early discontinuation was 3% with every-other-week and 5% with monthly dosing.
ApoB, non-HDL cholesterol and triglyceride effects tracked weight loss and remained consistent through maintenance.
Maintenance studies and dosing options
Part 2 evaluates transition from 17.5 mg weekly subQ to daily oral doses of 10–55 mg; a second study adds six higher-dose subQ arms for every-other-week and monthly dosing, with results expected in 2027 and around mid-year, respectively.
Monthly dosing retention was 90%; 35 mg monthly is being explored in a VANQUISH extension, with data intended for conference presentations and potential label language.
Potential maintenance options include weekly, every-other-week and monthly dosing, or transition from injection to oral therapy; oral maintenance targets retaining at least 75% of initial weight loss, particularly at mid-to-high doses.
A study switching patients from existing injectable treatments to VK2735 is considered worthwhile but is not planned near term.
Longer follow-up is planned in VANQUISH extensions through 52 weeks.
Phase 3 programs and market opportunity
VANQUISH-1 and VANQUISH-2 evaluate weekly subcutaneous VK2735 for 78 weeks; enrollment completed in 4Q25 and 1Q26, respectively, with data expected in 2H27.
SUNRISE-1 and SUNRISE-2 evaluate daily oral VK2735 for 68 weeks in obesity and obesity with diabetes; both began in 4Q26, target 560 participants each, and are expected to report data in 2028.
Four Phase 3 trials are underway; first Phase 3 data are targeted for H2 2027.
The obesity market is projected to exceed $150B by 2035, with a stated 16% CAGR; VK2735 is positioned for oral and injectable use and potential entry as the third obesity franchise.
- VK2735 advances toward obesity commercialization with oral, injectable and maintenance options.VKTX
Corporate presentation - VK2735 Phase 3 advances; $960M liquidity cushions investment and license risk.VKTX
Q3 2026 - VK2735 showed durable weight loss with less-frequent dosing as obesity Phase 3 trials advance.VKTX
Corporate presentation - Up to 22% weight loss and 97% maintenance achieved with flexible, well-tolerated VK2735 dosing.VKTX
Study result - Obesity program VK2735 advances in phase III with broad market and manufacturing strategies.VKTX
Morgan Stanley 24th Annual Global Healthcare Conference - VK2735 delivers up to 14.7% mean weight loss in Phase 2, with Phase 3 trials fully enrolled.VKTX
Corporate presentation - Phase III obesity trials fully enrolled; net loss rose as R&D spending surged, with $502M in cash.VKTX
Q2 2026 - VK2735 delivers up to 15% weight loss in late-stage trials with strong safety and cash reserves.VKTX
Corporate presentation - Q3 net loss rose to $90.8M as R&D spending surged; cash reserves remain strong at $715M.VKTX
Q3 2025
)
)
)
)
)
)
)
)